Can a One-Two punch of CAR-T and lenalidomide beat tough leukemia?

NCT ID NCT06762431

Recruiting now ⭐️ CURE ⭐️ Sponsor: Vitebsk Regional Clinical Cancer Centre Source: ClinicalTrials.gov ↗

First seen Aug 10, 2026 · Last updated Aug 14, 2026 · Updated 3 times

Summary

This trial is testing whether combining anti-CD19 CAR-T cell therapy with the drug lenalidomide can safely and effectively treat adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has returned or not responded to prior treatments. Participants will receive CAR-T cells along with lenalidomide, and some will also get obinutuzumab. The goal is to see if this combination can produce lasting remissions and improve outcomes for people with this hard-to-treat blood cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Anti-CD19 CAR T-cell therapy combined with lenalidomide (and obinutuzumab in some cycles)
What this could lead to: If successful, this combination could offer a durable, treatment-free remission for people with relapsed or refractory CLL, potentially a cure.
What could go wrong: This is an early-phase trial with a small number of patients, so results may not hold up. CAR-T therapy carries risks like severe immune reactions, infections, and prolonged low blood counts.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia Leukemia, B-Cell

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL) SMALL LYMPHOCYTIC LYMPHOMA (SLL)

Contacts and locations

Locations

Hematology/Oncology department
RECRUITING

Vitebsk, Select A State, 210023, Belarus

More trials for these conditions

Other studies related to the condition(s) this trial covers.